11:23 AM EST - Eupraxia Pharmaceuticals Inc. : Announced updates for its two clinical programs, EP-104IAR, its lead drug candidate in development for the treatment of knee osteoarthritis, and EP-104GI, a high-potential product candidate in development for the treatment of eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading down $0.32 at $5.54.
